Peptides are having a moment. Patient interest in BPC-157, growth hormone secretagogues, and other compounds for surgical recovery has grown dramatically — and so has the misinformation surrounding them.

Forums, online vendors, and wellness influencers have built an ecosystem where patients are self-administering compounds with real biological mechanisms, real effects, and real contraindications — without labs, without physician oversight, without any understanding of why sourcing and timing matter as much as the compounds themselves.

I study this biology seriously. I have reviewed the literature, built perioperative protocols around the mechanistic evidence, and thought carefully about where these compounds fit — and where they don't — in the context of shoulder surgery. What follows are six rules I consider non-negotiable. They apply regardless of which specific compounds are being considered, and they define the difference between intelligent supervised use of emerging science and self-experimentation with biology you don't fully understand.

None of the compounds I discuss carry FDA approval for perioperative use. All use is off-label and investigational. That is not a reason to dismiss the science — it is a reason to approach it carefully.

Rule 1:  Monitor Labs — Before, During, and After

Peptides that modulate the growth hormone and IGF-1 axis are not inert. They change measurable biology — and that biology needs to be measured.

A baseline IGF-1 level before starting any GH secretagogue tells you where you are starting from, helps calibrate dosing, and establishes a reference point if adverse effects emerge. A fasting glucose and metabolic panel screens for insulin resistance, which is both a contraindication concern and a variable that GH-axis stimulation directly affects.

You cannot optimize what you are not measuring. Anyone using peptides without baseline labs is flying without instruments.

‍

Lab monitoring at protocol milestones — typically at four to six weeks and again at twelve weeks — tells you whether the intervention is working as intended. IGF-1 rising into the physiologic optimization range is the signal you want. IGF-1 that fails to rise suggests either the compound is subtherapeutic or the patient's axis isn't responding. Either finding changes clinical management.

This is not optional. It is the minimum standard that separates physician-supervised optimization from self-experimentation.

Rule 2:  Know Your Source — The Compound on the Label and the Vial Are Not Always the Same

This is the rule the peptide community most reliably ignores — and it is the one with the most immediate safety implications.

Peptides purchased from gray-market online vendors have no FDA oversight, no mandatory sterility testing, no required certificate of analysis, and no accountability if the product is contaminated, underdosed, or mislabeled. These are not hypothetical risks. Contamination, endotoxin presence, and purity failures are documented problems in unregulated peptide supply chains.

A peptide that is 60% pure is not delivering a predictable 60% of the intended dose. It is delivering an unknown quantity of the intended compound plus an unknown quantity of something else — via injection, into a post-surgical patient.

‍

The standard for injectable peptide compounds is a 503A or 503B compounding pharmacy — licensed facilities operating under USP sterility standards with documented quality control. These pharmacies can provide a certificate of analysis on request, confirming identity, purity, and endotoxin testing for each batch. That document should exist for every injectable compound a patient uses.

Physician-prescribed compounds from a licensed compounding pharmacy are categorically different from self-sourced compounds from an online vendor. The distinction matters legally, medically, and practically. If a patient has an adverse outcome, the sourcing question will be the first one asked — and the answer matters.

Rule 3:  Match the Protocol to the Biology — Not the Other Way Around

The wellness space treats peptides like supplements — take them continuously, stack liberally, cycle on and off based on arbitrary schedules. This approach ignores the most important variable in perioperative biology: time.

Rotator cuff repair and shoulder arthroplasty both proceed through defined healing phases — inflammatory, proliferative, and remodeling — each with distinct cellular mechanisms and distinct windows of opportunity. A compound that drives angiogenesis is most valuable during the proliferative phase, weeks one through six, when the avascular enthesis is trying to establish a vascular supply. That same compound in week ten is delivering a signal into tissue that has already passed the window where vascularity is the limiting factor.

Timing is the protocol. Compounds without phase-matched timing are expensive noise.

‍

Growth hormone secretagogues take weeks to establish meaningful IGF-1 elevation. Starting them on the day of surgery — as many online protocols recommend — misses the pre-operative window entirely. The pre-load matters as much as the post-operative course.

A proper protocol maps specific compounds to specific healing windows with specific biological rationale for each. If someone cannot explain why a compound is being used during a particular phase — not just that it is good for healing, but which cellular mechanism it is targeting and when that mechanism is most relevant — it is not a protocol. It is guessing with expensive compounds.

Rule 4:  Optimize the Substrate — Peptides Amplify; They Don't Replace

This is the most commonly missed principle in the peptide optimization space, and it is the one with the most straightforward fix.

Peptides are signal molecules. BPC-157 signals for angiogenesis. CJC-1295 and Ipamorelin signal the pituitary to release growth hormone. IGF-1 signals tenocytes to synthesize collagen. But signals without substrate produce nothing. If the raw materials for collagen synthesis are not present — adequate dietary protein, collagen precursors, vitamin C, vitamin D, zinc — the signal has nowhere to go.

Peptides are the construction crew. Nutrition is the building materials. Sending a world-class crew to an empty lot accomplishes nothing.

‍

Optimizing the substrate means arriving at surgery — and recovering from it — with protein intake sufficient to support tissue synthesis, vitamin D levels above 40 ng/mL, and targeted collagen plus vitamin C supplementation timed around physical therapy sessions. The research data on collagen synthesis marker elevation with pre-PT collagen loading is real and accessible to every patient regardless of whether they use any prescription compounds at all.

Peptides layered on top of an optimized nutritional substrate are meaningfully more effective than peptides layered on top of a standard Western diet with suboptimal protein and micronutrient deficiencies. This is not a secondary consideration. It is foundational.

Rule 5:  Get Post-Operative Imaging — Track Your Outcome

Post-operative MRI is the only way to know whether a rotator cuff repair has actually healed. A patient can have full strength, minimal pain, and excellent range of motion — and have a re-tear. The clinical exam does not reliably distinguish between healed tissue and organized scar tissue. Imaging does.

In the context of a peptide optimization protocol, post-operative imaging serves an additional purpose: it is the only way to know whether the biological intervention did what it was intended to do. Without imaging, you have a patient who feels good — which tells you almost nothing about the structural quality of the repair.

Every patient who follows a structured protocol and undergoes post-operative MRI is contributing to the real-world evidence base that will eventually answer the clinical question rigorously.

‍

We are at the very beginning of this field. The randomized controlled trial that would validate or refute peptide optimization for rotator cuff repair does not yet exist. Every patient who tracks their outcome is participating — knowingly or not — in the generation of that evidence.

Getting post-op imaging is the right thing to do for your own outcome. It is also the right thing to do for every patient who comes after you. That is not a small consideration.

Rule 6:  Screen Contraindications First — Physician Oversight Is Not Optional

GH secretagogues elevate IGF-1. IGF-1 is a mitogenic signal — it drives cellular proliferation. In a patient with active or recent malignancy, that signal is not benign. This is an absolute contraindication, not a relative one, and it is not detectable from symptoms alone.

Significant insulin resistance changes the risk profile of GH-axis stimulation meaningfully. GH secretagogues transiently reduce insulin sensitivity — in a patient who is already metabolically compromised, that effect needs to be monitored. Fasting glucose and HbA1c are the minimum screens.

The biological optimization conversation needs to happen before surgery — not after. The pre-operative window is not recoverable. A patient who presents six weeks post-op asking about peptides has already missed the early proliferative phase entirely.

If you are not working with a physician who knows your labs, understands the healing phase biology, and has reviewed your imaging — you are not following a protocol. You are self-experimenting. Those are not the same thing.

‍

Physician oversight is not a formality. It is the mechanism by which contraindication screening, individualized dosing, lab monitoring, and outcome tracking actually happen. The difference between a well-supervised patient on a phase-matched protocol with baseline labs and a patient who self-administered compounds from an online vendor is not a matter of degree. It is a categorical difference — in what is actually happening biologically, and in who is accountable for the outcome.

The Short Version

If you want to use peptides to optimize your recovery from shoulder surgery, I am not here to discourage that interest. The biology is real, the mechanistic rationale is coherent, and the conversation is worth having.

But doing it right means labs before you start, compounds from a licensed pharmacy with documented purity, a protocol timed to your actual healing phase biology, a nutritional foundation that gives those signals somewhere to go, post-operative imaging to verify the outcome, and a physician who can screen for contraindications and supervise the process.

Six rules. None of them are complicated. All of them are non-negotiable.

About the Author

Patrick Denard, MD is a shoulder surgeon at Oregon Shoulder Institute in Medford, Oregon. He is ranked #2 in North America for rotator cuff repair and #17 globally for shoulder replacement, and has authored over 300 peer-reviewed publications.

Disclosure

This post is for educational purposes only and does not constitute medical advice. The compounds discussed are not FDA-approved for the applications described. Always consult a qualified physician before initiating any medical intervention. Visit oregonshoulder.com for more information.

‍